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Abstract
Background: The aim of this study was to evaluate the proper indication of adjunctive BRAFV600E mutation analysis at the
time of ultrasound-guided fine-needle aspiration in the diagnosis of thyroid nodules.
Methods: This study included 518 nodules in 479 patients who underwent ultrasound-guided fine-needle aspiration with
BRAFV600E mutation. We calculated and compared the diagnostic performances of cytology and cytology with BRAFV600E
mutation analysis to detect malignancy among thyroid nodules according to ultrasound features and size.
Results: Sensitivity, negative predictive value, and accuracy of cytology with BRAFV600E mutation analysis were significantly
higher than those of cytology alone in thyroid nodules with suspicious ultrasound features, regardless of size. Diagnostic
performances did not show significant differences between cytology and cytology with BRAFV600E mutation analysis in
nodules without any suspicious ultrasound features, regardless of size.
Conclusion: The BRAFV600E mutation analysis was a useful adjunctive diagnostic tool in the diagnosis of thyroid nodules
with suspicious ultrasound features regardless of size.
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Introduction
Among the various molecular events related to thyroid cancer,
BRAFV600E mutation is a highly specific somatic mutation for
papillary thyroid cancer [1–3]. An activating point mutation of the
T1799A point BRAF gene results in a valine-to-glutamic acid
replacement at amino acid V600, resulting in the constitutive
tumorogenesis [1,4]. The prevalence of the mutation in papillary
thyroid cancer is highly variable especially according to region,
ranging from 29% to 83% in different studies from different areas
of the world [4]. Among patients diagnosed as papillary thyroid
cancer in Korea, the prevalence of BRAFV600E mutation has been
reported up to 84% [4–8].
Although detecting BRAFV600E mutation plays an additional
role in the definitive diagnosis of thyroid nodules [8–10],
performing routine BRAFV600E mutation analysis in addition to
fine-needle aspiration (FNA) may be questioned, when considering
its cost-effectiveness. Therefore, a proper indication for perform-
ing additional BRAFV600E mutation analysis to FNA is needed.
Although a few studies demonstrated proper guidelines in selecting
which thyroid nodules for testing BRAFV600E mutation, these
studies have mostly focused on ultrasound (US) features and the
test point of analysis [4,9,11,12]. When considering that the
prevalence of BRAFV600E mutation was higher in patients with
papillary thyroid cancer .1 cm in size than in patients with
papillary thyroid microcarcinoma [8,13–15], size of the thyroid
nodule can act as an indicative factor in deciding whether to
perform additional BRAFV600E mutation analysis to FNA.
Therefore, this study was to investigate the proper indication of
adjunctive BRAFV600E mutation analysis at the time of ultrasound-
guided fine-needle aspiration (US-FNA) in the diagnosis of thyroid
nodules.
Materials and Methods
The institutional review board of severance hospital approved of
this retrospective observational study and required neither patient
approval nor informed consent for our review of patients’ images
and records. However, written informed consent was obtained
from all patients for US-FNA and BRAFV600E mutation analysis
prior to each procedure as a daily practice.
Study Population
A total of 779 nodules in 722 patients who had US-FNA and
BRAFV600E analysis from January 2009 to October 2010 were
initially enrolled in this study. Among them, 261 nodules were
excluded for following reasons; further follow-up including second
US or US-FNA was not performed (n= 191), follow-up US-FNA
revealed cellular paucity, atypia, follicular or Hurthle cell
neoplasm, suspicious malignancy, or malignancy but the patient
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had not undergone surgery (n = 66), follow-up US showed increase
in size in nodules diagnosed as benign on cytology without further
cytopathologic confirmation (n= 3), and missing radiologic reports
(n = 1). A total of 518 nodules in 479 patients were finally included
in this study (Figure 1). Of 518 nodules, 331 nodules from 300
patients were confirmed pathologically (Surgery group), and 187
nodules from 182 patients were clinically observed by follow-up
FNA (n= 112) or follow-up US (n= 75). Mean period of follow-up
US was 14.7 months. Two patients had two nodules each, of
which one were pathologically confirmed after surgery and the
other underwent observation. One patient had three nodules of
which two were pathologically confirmed and the other underwent
observation.
US Analysis
For evaluation of the thyroid glands and cervical lymph nodes, a
5–12 MHz linear probe (iU22, Philips Medical Systems, Bothell,
WA) or a 6–13 MHz linear probe (EUB-7500, Hitachi Medical,
Tokyo, Japan) were used. Compound imaging was used in all
images from the iU22 machine. Seven board-certified radiologists
specialized in thyroid imaging with 1–15 years of experiences
performed US and subsequent US-FNA.
US features of all thyroid nodules which had undergone US-
FNA were prospectively recorded according to the internal
component, echogenicity, margin, calcification, and shape at the
time of US examination. Malignant US features were markedly
hypoechogenicity, irregular or microlobulated margin, presence of
microcalcifications, and taller than wide shape [16]. Thyroid
nodules showing one or more suspicious US features described
above were assessed as suspicious malignant, while those without
any suspicious US features were assessed as probably benign [16].
Size of thyroid nodule was also recorded measuring the longest
diameter.
US-FNA and Cytologic Analyses
US-FNA was done by the same radiologist who performed US.
Fine-needle aspiration was performed on the nodules showing
suspicious features, and if none showed any suspicious US features,
FNA was performed targeting at the nodule with the largest size.
Each nodule was aspirated at least twice using freehand technique
with a 23-gauge needle attached to 2-mL disposable plastic
syringe. Obtained samples were expelled on to glass slides,
smeared and placed immediately into 95% alcohol for Papanico-
laou staining. One of the five cytopathologists specializing in
thyroid cytology interpreted the smeared samples. Cytopatholo-
gists were not present during the biopsy procedures, but special
staining was performed if needed. Cytology reports of June 2009 to
November 2009 were based on the following 5 categories; 1)
benign, 2) indeterminate cytology (follicular neoplasm or Hurthle
cell neoplasm), 3) suspicious for papillary thyroid cancer, 4)
malignant and 5) inadequate [9]. After December 2009 to the
present, the Bethesda classifications are used in the cytology
reports of thyroid aspiration studies [17].
BRAFV600E mutation analysis was performed with the remain-
ing material in the syringe used in aspiration. Remaining material
was rinsed in 1 mL of normal saline, and was subjected to the
BRAFV600E mutation analysis.
Dual Priming Oligonucleotide-based Multiplex
Polymerase Chain Reaction (DPO-PCR)
BRAFV600E mutation analysis using the DPO-PCR technology
was performed using the Seeplex BRAFACE detection system
(Seegene, Seoul, Korea) as described previously [13,14].
Data and Statistical Analysis
We used cytopathological results as the ‘‘gold standard’’,
pathologically confirmed malignancies classified into the positive
group, and pathologically confirmed or clinical benign nodules
Figure 1. Diagram of study population. A total of 518 nodules in 479 patients were finally included in this study, and 331 nodules from 300
patients were confirmed pathologically, and 187 nodules from 182 patients were clinically observed by follow-up FNA (n= 112) or follow-up US
(n = 75). Abbreviations: US-FNA, ultrasound-guided fine-needle aspiration; FN, follicular neoplasm; Op, operation; FU US, follow-up ultrasound; FU
FNA, follow up fine-needle aspiration; FNA, fine-needle aspiration.
doi:10.1371/journal.pone.0064505.g001
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classified into the negative group. Categorical data was summa-
rized using frequencies and percentages. x2 test was used in
analysis of categorical variables, while independent two-sample t
test was used in continuous variables.
The cytologic grouping and management was based on whether
the recommendation was follow-up (clinical follow-up or repeat
aspiration) or surgery, according to the Bethesda classifications
[17]. Malignancy, suspicious for malignancy, indeterminate results
from the study period before December 2009, suspicious for
follicular neoplasm or follicular neoplasm on cytology results were
included in the ‘‘positive’’ cytology group. The malignant
cytologic diagnoses were considered positive cytology when
calculating diagnostic values of FNA. To calculate diagnostic
performances of FNA, we compared the results to the ‘‘gold
standard’’. True-positives (TP) were defined as nodules with
‘‘positive’’ cytology and a corresponding ‘‘positive’’ gold standard
result. True-negatives (TN) had both ‘‘negative’’ cytology and gold
standard one. False-negatives (FN) were defined as nodules with
‘‘negative’’ cytology and ‘‘positive’’ gold standard one. False-
positives (FP) had positive cytology and ‘‘negative’’ gold standard
one. To calculate diagnostic performances of FNA with
BRAFV600E mutation analysis, a nodule was considered ‘‘positive’’
group when either FNA or BRAFV600E mutation was positive. The
following statistical values were calculated as: Sensitivity =TP/
(TP+FN) 6 100; specificity =TN/(TN+FP) 6 100; positive
predictive value =TP/(TP+FP) 6 100; negative predictive va-
lue =TN/(TN+FN) 6 100; accuracy= (TP+TN)/
(TP+TN+FP+FN)6 100. We calculated diagnostic performances
of FNA and FNA with BRAFV600E mutation analysis for detecting
malignancy according to US features and size of the nodule. We
also compared the diagnostic performances of FNA and FNA with
BRAFV600E mutation analysis for detecting malignancy according
to US features and size, using logistic regression with generalized
estimating equation method.
Analysis was performed using SAS software (version 9.1.3; SAS
Institute, Cary, NC). Statistical significance was assumed when the
P value was less than 0.05. All reported P values are 2-sided.
Results
Patient and Nodule Characteristics
Of the total 518 FNA with additional BRAFV600E mutation
analysis performed, 317 (61.2%) nodules were confirmed as
malignancy, and the remaining 201 (38.8%) as benign (Table 1).
The mean age of patients was 48.6611.7 years. Size of the nodules
ranged from 2 mm to 52 mm (mean 10.567.3 mm). Mean age of
the malignant group (46.1611 years) was younger than the benign
group (52.7611.6 years), showing statistical significance
(P,0.001). Mean size of the benign nodules was 12.568.5 mm,
which was larger than the malignant nodules (9.266.1 mm) with
statistical significance (P,0.001).
Of the 317 nodules confirmed as malignant, 250 (78.9%)
showed BRAFV600E mutation. Among the 201 benign nodules,
three (1.5%) showed BRAFV600E mutation, two of which were
pathologically confirmed as benign (adenomatous hyperplasia) by
surgery, and one had undergone follow-up US for over a year with
no interval change of size or characteristic.
Analyses of All 518 Thyroid Nodules
Table 2 summarizes the diagnostic performances of FNA and
FNA with BRAFV600E mutation analysis. In all 518 thyroid
nodules, additional BRAFV600E mutation analysis improved
sensitivity of FNA alone from 67.2% to 78.9% (P,0.001),
accuracy from 79.9% to 86.5% (P,0.001), and negative predictive
value from 65.9% to 74.7% (P,0.001). Specificity and positive
predictive value did not show statistically significant differences
between FNA and FNA with BRAFV600E mutation analysis.
Of the 386 nodules with suspicious US features, sensitivity,
accuracy, and negative predictive value were higher in FNA with
BRAFV600E mutation analysis compared to FNA alone, 80.8% to
68.7% (P,0.001), 85% to 75.9% (P,0.001), and 60.7% to 48.9%
(P,0.001), respectively, showing statistical significance. Specificity
and positive predictive value did not show statistically significant
differences between FNA and FNA with BRAFV600E mutation
analysis. In the 132 nodules without any suspicious US features,
none of diagnostic performances showed statistically significant
improvement with BRAFV600E mutation analysis.
Analyses of the 175 Nodules Larger than 10 mm
Sensitivity, negative predictive value, and accuracy of FNA with
BRAFV600E mutation analysis were higher than FNA alone (84.1%
to 75.6%, 87.5% to 82.3%, and 91.4% to 88.6%) with statistical
significance in the 175 thyroid nodules larger than 10 mm.
Specificity and positive predictive value did not show statistically
significant differences between FNA and FNA with BRAFV600E
mutation analysis.
Similar results were observed in the 99 nodules larger than
10 mm showing suspicious US features. Sensitivity, accuracy, and
Table 1. Cytological diagnoses of 518 nodules according to initial fine-needle aspiration results.*
Cytological diagnoses Malignant Benign
Total BRAF
V600E mutation Total BRAF
V600E mutation
Positive Negative Positive Negative
Non-diagnostic (n = 20) 13/20 (65) 1/13 (7.7) 12/13 (92.3) 7/20 (35) 0/7 (0) 7/7 (100)
Benign (n = 194) 10/194 (5.2) 4/10 (40) 6/10 (60) 184/194 (94.8) 2/184 (1.1) 182/184 (98.9)
Atypia (n = 22) 16/22 (72.7) 5/16 (31.3) 11/16 (68.8) 6/22 (27.3) 1/6 (16.7) 5/6 (83.3)
Follicular neoplasm or suspicious
for follicular neoplasm (n = 5)
1/5 (20) 0/1 (0) 1/1 (100) 4/5 (80) 0/4 (0) 4/4 (100)
Suspicious for malignancy (n = 64) 64/64 (100) 27/64 (42.2) 37/64 (57.8) 0/64 (0)
Malignant (n = 213) 213/213 (100) 139/213 (65.3) 74/213 (34.7) 0/213 (0)
Total 317 201
*Except where noted, data are number/total number (%).
doi:10.1371/journal.pone.0064505.t001
Proper Indication of BRAFV600E Mutation Testing
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64505
negative predictive value were improved in FNA with BRAFV600E
mutation analysis compared to FNA, 89.3% to 81.3% (P= 0.012),
91.9% to 85.9% (P= 0.013), and 75% to 63.2% (P= 0.016),
respectively. Specificity and positive predictive value show same
values between FNA and FNA with BRAFV600E mutation analysis.
Of the 76 nodules larger than 10 mm without any suspicious US
features, all values did not show statistically significant differences
between FNA and FNA with BRAFV600E mutation analysis.
Analyses of the 343 Nodules Equal to or Smaller than
10 mm
Of the 343 nodules equal to or smaller than 10 mm, additional
BRAFV600E mutation analysis showed improvement to FNA in
sensitivity (77% to 64.3%) and negative predictive value (66.5% to
56.3%), with statistical significance. Specificity, accuracy, and
positive predictive value were not improved with additional
BRAFV600E mutation analysis, without statistical significance.
Diagnostic performances according to US features were
analyzed among the 343 nodules. Among them, 287 were assessed
Table 2. Diagnostic performances of FNA and FNA with additional BRAFV600E mutation analysis in the detection of malignancy
according to US features and size of the nodules.*.
Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%)
Overall (n = 518) Total (n = 518)
FNA 67.2 (213/317) 100 (201/201) 79.9 (414/518) 100 (213/213) 65.9 (201/305)
FNA with BRAFV600E mutation 78.9 (250/317) 98.5 (198/201) 86.5 (448/518) 98.8 (250/253) 74.7 (198/265)
P value{ ,0.001 0.081 ,0.001 0.081 ,0.001
Suspicious US feature (n=386)
FNA 68.7 (204/297) 100 (89/89) 75.9 (293/386) 100 (204/204) 48.9 (89/182)
FNA with BRAFV600E mutation 80.8 (240/297) 98.9 (88/89) 85 (328/386) 99.6 (240/241) 60.7 (88/145)
P value ,0.001 0.315 ,0.001 0.316 ,0.001
Without suspicious US feature (n =132)
FNA 45 (9/20) 100 (112/112) 91.7 (121/132) 100 (9/9) 91.1 (112/123)
FNA with BRAFV600E mutation 50 (10/20) 98.2 (110/112) 90.9 (120/132) 83.3 (10/12) 91.7 (110/120)
P value 0.306 0.154 0.563 0.121 0.422
.10 mm (n=175) Total (n = 175)
FNA 75.6 (62/82) 100 (93/93) 88.6 (155/175) 100 (62/62) 82.3 (93/113)
FNA with BRAFV600E mutation 84.1 (69/82) 97.8 (91/93) 91.4 (160/175) 97.2 (69/71) 87.5 (91/104)
P value 0.006 0.153 ,0.001 0.151 0.013
Suspicious US feature (n=99)
FNA 81.3 (61/75) 100 (24/24) 85.9 (85/99) 100 (61/61) 63.2 (24/38)
FNA with BRAFV600E mutation 89.3 (67/75) 100 (24/24) 91.9 (91/99) 100 (67/67) 75 (24/32)
P value 0.012 – 0.013 – 0.016
Without suspicious US feature (n =76)
FNA 14.3 (1/7) 100 (69/69) 92.1 (70/76) 100 (1/1) 92 (69/75)
FNA with BRAFV600E mutation 28.6 (2/7) 97.1 (67/69) 90.8 (69/76) 50 (2/4) 93.1 (67/72)
P value 0.295 0.151 0.563 0.046 0.405
#10 mm (n=343) Total (n = 343)
FNA 64.3 (151/235) 100 (108/108) 75.5 (259/343) 100 (151/151) 56.3 (108/192)
FNA with BRAFV600E mutation 77 (181/235) 99.1 (107/108) 84 (288/343) 99.5 (181/182) 66.5 (107/161)
P value ,0.001 0.315 0.094 0.316 ,0.001
Suspicious US feature (n=287)
FNA 64.4 (143/222) 100 (65/65) 72.5 (208/287) 100 (143/143) 45.1 (65/144)
FNA with BRAFV600E mutation 77.9 (173/222) 98.5 (64/65) 82.6 (237/287) 99.4 (173/174) 56.6 (64/113)
P value ,0.001 0.314 ,0.001 0.316 ,0.001
Without suspicious US feature (n =56)
FNA 61.5 (8/13) 100 (43/43) 91.1 (51/56) 100 (8/8) 89.6 (43/48)
FNA with BRAFV600E mutation 61.5 (8/13) 100 (43/43) 91.1 (51/56) 100 (8/8) 89.6 (43/48)
P value – – – – –
Abbreviations: FNA, fine-needle aspiration; US, ultrasound; PPV, positive predictive value; NPV, negative predictive value.
*Data presented in parentheses are number of nodules.
{P values were calculated using generalized estimating equation analysis.
doi:10.1371/journal.pone.0064505.t002
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as suspicious malignant, and the remaining 56 as probably benign.
Sensitivity, accuracy, and negative predictive value were signifi-
cantly improved in FNA with BRAFV600E mutation analysis
compared to FNA alone in the 287 nodules with suspicious US
features, 77.9% to 64.4% (P,0.001), 82.6% to 72.5% (P,0.001),
and 56.6% to 45.1% (P,0.001), respectively. Diagnostic perfor-
mances showed similar values when comparing FNA to FNA with
BRAFV600E mutation analysis in the 56 thyroid nodules without
any suspicious US features.
Discussion
To the present date, FNA has shown acceptable diagnostic
performances in the diagnosis of malignancy in thyroid nodules
[18–20]. There are several limitations of FNA, however, such as
false-negative and non-diagnostic results [20]. Many studies
regarding molecular studies have been conducted to overcome
these diagnostic limitations of FNA [11,21,22]. There have been
several genetic abnormalities associated with thyroid carcinoma
including point mutations such as those in the RAS and BRAF
genes, and chromosomal rearrangements such as RET/PTC and
PAX8/PPARc [2]. Papillary carcinoma, the most common
thyroid malignancy, harbors BRAFV600E, RET/PTC rearrange-
ment, or the frequently found RAS mutations [23]. RAS genes
and PAX8/PPARc rearrangement are found more in follicular
carcinomas [3,23]. A recent study further demonstrated that
BRAFK601E was associated with the follicular variant type of
papillary thyroid carcinoma [24]. Among them, BRAFV600E
mutation analysis showed good performances. However, when
considering its cost-effectiveness, it is unclear whether if
BRAFV600E mutation analysis should routinely accompany US-
FNA in the diagnosis of malignancy in patients with thyroid
nodules. A proper indication for an adjunctive BRAFV600E
mutation analysis is required. Recent studies demonstrated that
reflex molecular testing including the BRAFV600E mutation can
offer significant improvement in the preoperative diagnosis of
thyroid cancer, especially in those showing indeterminate cytologic
results including follicular lesion with atypia of uncertain
significance, and suspicious for papillary carcinoma [25,26].
Unfortunately, reflex molecular testing cannot always be adapted
in all institutions, therefore, supporting the need for a proper
guideline for the BRAFV600E mutation analysis.
Several studies regarding proper indications for the additional
BRAFV600E mutation analysis demonstrated that this was more
helpful when applied to nodules with suspicious features on US
[4,9,11,12], and at the time of initial US-FNA [9]. Also, the size of
papillary thyroid cancer may affect the diagnostic performance of
BRAFV600E mutation analysis, when regarding the different
prevalence of BRAFV600E mutation in papillary thyroid micro-
carcinoma and papillary thyroid cancer larger than 10 mm [8,13–
15]. In this study, we investigated the diagnostic performance of
FNA and FNA with BRAFV600E mutation analysis to evaluate a
proper indication for the BRAFV600E mutation analysis, consid-
ering the size and US features of the thyroid nodules. Results of
our study show that the prevalence of BRAFV600E mutation was
higher in papillary thyroid cancer (51/82, 62.2%) than papillary
thyroid microcarcinoma (125/235, 53.2%). Sensitivity, accuracy,
and negative predictive value of FNA with BRAFV600E mutation
analysis were significantly higher than those of FNA alone in
thyroid nodules with suspicious US features, regardless of its size.
All diagnostic performances of FNA with BRAFV600E mutation
analysis did not show significant differences compared to FNA
alone in nodules without any suspicious US features, regardless of
its size.
In the previous studies regarding the diagnostic performances of
BRAFV600E mutation analysis, specificity was reported to be
almost 100% [12], but several false-positive cases were reported in
Korea [7,8,10]. These false-positive cases reported in literature are
thought to be caused by applying highly sensitive DPO-PCR or
pyrosequencing analysis. These techniques focus on improving
diagnostic sensitivity, which may result in false-positive cases [7].
In this study, three cases showed false-positive results among the
201 benign nodules; two of which were pathologically confirmed
as benign by surgery, and one had undergone follow-up US for
over one year. To reach 100% specificity to detect BRAFV600E
mutation at pyrosequencing, cut-off values were refitted to scarify
sensitivity [7]. Further studies are required to evaluate the false
positive results of BRAFV600E mutation and consensus also should
be needed to interpret and apply the results in patients with
thyroid nodules.
There are several potential limitations to this study. First, the
nodules which had not undergone surgery were included, based on
the cytology results. This may have affected our results in ways of
false-negative or false-positive cytologic results [27,28]. Second, we
divided groups based on the presence of suspicious US features.
However, interobserver variability among radiologists in inter-
preting US images may have affected the results [29–31], which
also may not be reproducible in other institutions. Third, sample
size was different in thyroid nodules when grouped into those
larger or equal to or smaller than 10 mm, which may have
affected the results.
Conclusion
The BRAFV600E mutation analysis was a useful adjunctive
diagnostic tool in the diagnosis of thyroid nodules with suspicious
US features regardless of the size.
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